Navigation Links
Cardiogenesis Reports Third Quarter 2008 Results
Date:11/13/2008

IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its third quarter ended September 30, 2008.

Third Quarter Financial Results

Sales in the third quarter of 2008 totaled $2,618,000, a 25% decrease from the prior year third quarter sales of $3,486,000. The lower revenue in the current year quarter is primarily attributable to a $534,000, or 59%, decrease in capital sales, and a $326,000, or 14%, decrease in disposable handpiece revenue as compared with the prior year quarter.

Sales in the first nine months of 2008 totaled $9,719,000, an increase of approximately $427,000 or 5% from sales of $9,292,000 in the first nine months of 2007. The year to date increase as compared with the prior year period is primarily attributable to a $712,000, or 38%, increase in capital sales offset by a $255,000, or 4%, decrease in disposable handpiece revenue.

The Company reported a third quarter 2008 operating loss of $310,000 as compared with an operating income of $679,000 in the prior year quarter. The Company's net loss for the quarter was $308,000, or $0.01 per diluted share, as compared with a net income of $590,000, or $0.01 per diluted share, in the 2007 third quarter.

For the first nine months of 2008, Cardiogenesis reported operating income of $235,000 as compared with $888,000 for the same period in the prior year. Net income for the first nine months of 2008 was $258,000, or $0.01 per diluted share, compared with $662,000, or $0.01 per diluted share, for the first nine months of 2007.

Gross profit decreased by $603,000 to $2,144,000 in the current year quarter as compared with $2,747,000 for the 2007 third quarter. Gross margin was 82% of net revenues for the quarter ended September 30, 2008 as compared with a 79% gross margin in the third
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
2. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. China Biologic Products Reports Strong Third Quarter 2008 Results
6. Imagenetix, Inc. Reports Second Quarter and Six Month Results
7. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... LifeCell Dx and its founder, Dr. Lani ... Advanced Semen Analysis before they do anything else about ... risk factors for struggling couples.Too often, the traditional path ... the infertility. Infertility is fairly equally divided between the ... least complicated and inexpensive analysis that provides far more ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
(Date:3/5/2015)... , March 5, 2015  In response to the ... Miami, FL on February 12, 2015. ... of strong financial health and their SUDOSCAN® devices have ... has indicated. Furthermore, Impeto prefers to have the courts decide ... are more than 40 articles written by Key Opinion ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... Jennerex, Inc., a clinical-stage biotherapeutics company focused ... targeted oncolytic products for cancer, today announced the ... with aggregate gross proceeds of approximately $8.6 million. ... be used to advance the Company,s oncology product ...
... at the National Institute of Standards and Technology (NIST) ... world,s darkest material‑a forest of carbon nanotubes that reflects ... the infrared spectrum., NIST will use the new ultra-dark ... Letters ,* to make precision laser power measurements for ...
... 18 Regenicin, Inc. (OTC Bulletin Board: ... that it has completed an initial $3.25 million funding ... license to know-how technology controlled by Lonza Walkersville ("Lonza ... Ltd. (SIX: LONN), one of the world,s leading suppliers ...
Cached Biology Technology:Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million 2Extreme darkness: Carbon nanotube forest covers NIST's ultra-dark detector 2Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and Voice Biometrics ... Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Middle ... Latin America . Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... differences in satellite images may be an effective way ... over time, with potential implications for measuring biodiversity as ... Matteo Convertino from the University of Florida and colleagues ... The authors designed statistical models to estimate two ...
... reef in the Koster Fjord, is under threat of ... Gothenburg have started a restoration project where healthy corals ... placed on the Scken reef. Coral reefs are ... one reef-building coral species exists, a cold-water coral called ...
... animals more prone to extinction than others? A new study ... roughly 500 million years of fossil data for marine invertebrates ... consistently hard hit even when populations are large, the ... the Earth,s surface. But because monitoring data are harder to ...
Cached Biology News:Sweden's only coral reef at risk of dying 2Sweden's only coral reef at risk of dying 3Fossil study helps pinpoint extinction risks for ocean animals 2
...
...
...
... Sheep polyclonal to Decorin ( ... Antigen: Synthetic ... to amino acids 6-19 of Human ... molecule bone proteoglycan II). ...
Biology Products: